Prostat Kanseri Tanı ve Takibinde Güncel Psma Pet Radyofarmasötikleri ve Klinik Uygulamalar
Synopsis
Prostate-specific membrane antigen (PSMA)-targeted positron emission tomography/computed tomography (PET/CT) has become a key molecular imaging tool for initial staging, localization of biochemical recurrence, and selection of patients for PSMA-targeted radioligand therapy in prostate cancer. Radiopharmaceuticals such as 68Ga-PSMA-11, 18F-DCFPyL, and 18F-PSMA-1007 share the same biological target but differ in physical characteristics, production logistics, and excretion pathways. This chapter summarizes current recommendations from the EAU, NCCN, ESMO, and EANM/SNMMI together with major prospective trials, with particular emphasis on risk-adapted primary staging, correct definitions of biochemical recurrence after radical prostatectomy and radiotherapy, imaging protocols, interpretation pitfalls, and theranostic applications. PSMA PET/CT provides greater staging accuracy than conventional imaging particularly in patients with unfavorable intermediate-risk and high-risk disease and can localize recurrent disease even at low PSA levels. However, a negative PSMA PET study does not exclude microscopic disease; findings should therefore be interpreted together with PSA kinetics, pathological risk factors, clinical context, and the intended treatment strategy.
References
Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer. 1998;82(11):2256-2261.
Nükleer Tıp ve Moleküler Görüntüleme. Cilt 2: Metodoloji ve Klinik Uygulamalar. Editör: Kibar M. Akademisyen Yayınevi; 2023.
Oh SW, Cheon GJ. Prostate-Specific Membrane Antigen PET Imaging in Prostate Cancer: Opportunities and Challenges. Korean J Radiol. 2018;19(5):819-831. doi:10.3348/kjr.2018.19.5.819.
Fendler WP, Eiber M, Beheshti M, et al. PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023;50:1466-1486. doi:10.1007/s00259-022-06089-w.
European Association of Urology. EAU Guidelines on Prostate Cancer. Sections on classification/staging, treatment of biochemical recurrence and follow-up. 2026 edition. Accessed September 2026.
Schaeffer EM, Srinivas S, Adra N, et al. NCCN Guidelines Insights: Prostate Cancer, Version 3.2024. J Natl Compr Canc Netw. 2024. PMID:38626801.
Gillessen S, et al. Local and locoregional prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2026. doi:10.1016/j.annonc.2025.12.009.
Fizazi K, Attard G, Azad AA, et al. Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2026;37(5):590-607. doi:10.1016/j.annonc.2026.01.015.
Hofman MS, Lawrentschuk N, Francis RJ, et al.; proPSMA Study Group Collaborators. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208-1216. doi:10.1016/S0140-6736(20)30314-7.
Pienta KJ, Gorin MA, Rowe SP, et al. A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with 18F-DCFPyL in Prostate Cancer Patients (OSPREY). J Urol. 2021;206(1):52-61. doi:10.1097/JU.0000000000001698.
Morris MJ, Rowe SP, Gorin MA, et al. Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study. Clin Cancer Res. 2021;27(13):3674-3682. doi:10.1158/1078-0432.CCR-20-4573.
Giesel FL, Hadaschik B, Cardinale J, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44(4):678-688. doi:10.1007/s00259-016-3573-4.
Sartor O, de Bono J, Chi KN, et al.; VISION Investigators. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021;385(12):1091-1103. doi:10.1056/NEJMoa2107322.
Fanti S, Hadaschik B, Herrmann K. Proposal for Systemic-Therapy Response-Assessment Criteria at the Time of PSMA PET/CT Imaging: The PSMA PET Progression Criteria. J Nucl Med. 2020;61(5):678-682. doi:10.2967/jnumed.119.233817.
Gafita A, Rauscher I, Weber M, et al. Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study. J Nucl Med. 2022;63(11):1651-1658. PMID:35422442.